NF-κB

Overview

Nuclear Factor kappa-B (NF-κB) is a transcription factor and central signaling pathway that regulates the expression of genes involved in inflammation, immunity, cell proliferation, and apoptosis. In its inactive state, NF-κB is sequestered in the cytoplasm bound to inhibitory proteins; upon activation via multiple upstream signals, it translocates to the nucleus to initiate transcriptional programs. NF-κB activation is triggered by diverse stimuli including cytokines (such as TNF-α), pathogen-associated molecular patterns detected by toll-like receptors (TLR4), and cellular stress signals. The pathway is fundamental to innate and adaptive immune responses but becomes pathologically dysregulated in chronic inflammatory diseases, cancer, aging, and degenerative conditions.

Because NF-κB controls pro-inflammatory gene expression and cell survival, its inhibition has emerged as a major therapeutic strategy across multiple disease indications. The challenge lies in targeting NF-κB selectively to suppress pathological inflammation while preserving protective immune functions—a balance reflected in recent research efforts using natural compounds, synthetic inhibitors, and combination therapies.

Role in Recent Research

Recent studies demonstrate that NF-κB serves as both a key mechanistic driver of disease pathology and a validated therapeutic target across oncology, immunology, and regenerative medicine applications.

Therapeutic Targeting in Cancer and Inflammation

NF-κB has emerged as a target for rational drug design and structure-based therapeutics. Molecular docking studies have explored favorable binding of candidate inhibitors—including gold-cerium oxide nanohybrids and small molecules such as 5-fluorouracil—to NF-κB alongside other cancer-associated targets like p53 and kinase proteins. In cancer immunotherapy, NK cell-mediated attack of glioblastoma cells induces TFPI2 expression through IL1β- and TNFα-driven NF-κB activation, suggesting that NF-κB modulation may enhance anti-tumor immune surveillance. Additionally, sustained MAPK inhibition in cancer cells induces interferon and NF-κB signaling, which paradoxically promotes cell state transition and confers drug resistance—highlighting the complexity of NF-κB's role in adaptive therapeutic resistance.

NF-κB in Inflammatory Pathway Architecture

Current research reveals that NF-κB functions as a hub within interconnected signaling cascades. The TLR4/MyD88/NF-κB axis is a critical inflammatory pathway implicated in acute respiratory distress syndrome, exertional heat stroke-induced brain injury, and infection-driven organ damage. In a Helicobacter-infected artificial liver model, infection induced a 1.6-fold activation of NF-κB accompanied by threefold increases in apoptosis and 1.5-fold upregulation of TNF-α. Nanocurcumin suppresses this TLR4/MyD88/NF-κB signaling to attenuate heat stroke-induced brain injury in rats. Beyond TLR signaling, NF-κB coordinates with PI3K/Akt, MAPK, and STAT pathways; for example, in osteoarthritis treatment, hydrogel microspheres suppress NF-κB while potentiating PI3K/Akt/eNOS signaling to remodel the microenvironment and promote macrophage M2 polarization (increasing the CD206/CD86 ratio 7.7-fold). Similarly, engineered hydrogels with zinc-arginine cross-linkers achieve therapeutic benefit for limb ischemia-reperfusion injury by suppressing NF-κB and upregulating IL-10.

Natural Compound Inhibitors and Combination Therapies

A significant body of research evaluates natural compounds that suppress NF-κB to treat aging, inflammation, and metabolic disease. myricetin effectively suppresses intestinal aging by inhibiting NF-κB activation and alleviating inflammation in electrostatic microsphere intestinal aging models. Aged garlic extract (AGE) combined with dexamethasone (DEX) broadens and enhances inhibition of inflammatory mediators compared to monotherapy while further suppressing NF-κB expression in the context of acute respiratory distress syndrome. hesperidin and orange peel aqueous extract show strong predicted binding affinities for NADPH oxidase subunits, cyclooxygenases-1 and -2, p38 MAPK, and NF-κB, demonstrating multi-target anti-inflammatory activity. astaxanthin reduces neuroinflammation and apoptosis in ischemic stroke by inhibiting toll-like receptor signaling and downregulating NF-κB alongside related proteins (MyD88, IL-1β, IL-6, caspase-3). Traditional Chinese Medicine formulations such as Shaoyao Gancao Decoction ameliorate rheumatoid arthritis specifically via inhibition of the TNF-α/NF-κB signaling pathway, and Shenling Baizhu Powder modulates NF-κB expression in ulcerative colitis models alongside changes in Akt1, mTOR, TLR2/TLR4, ERK1/2, STAT1, MyD88, and BCL2.

Emerging Mechanisms and Clinical Relevance

MIF (macrophage migration inhibitory factor) signaling via CD74 drives NF-κB activation to establish a metabolically sustained prometastatic state in brain metastasis, linked to oxidative phosphorylation and mitochondrial plasticity. In T-cell costimulatory receptor engineering, ICCR engagement with ICAM1 triggers NF-κB signaling independently of TCR-peptide/MHC recognition, but full T-cell cytotoxic function remains dependent on intact TCR signaling—revealing NF-κB as one of multiple integration points in immune activation. These findings underscore that NF-κB inhibition must be contextualized within pathway hierarchies and feedback mechanisms to maximize therapeutic benefit while minimizing immune suppression.

Collectively, recent research validates NF-κB as a high-priority therapeutic target while demonstrating that effective intervention requires understanding its position within broader signaling networks—a principle guiding development of next-generation anti-inflammatory and anti-cancer therapeutics.

Key Publications

• NEWJun Biomedical publication details. (PubMed Database, 2026, PMID 42240071)
• NEWJun Biomedical publication details. (PubMed Database, 2026, PMID 42275210)
• NEWJun Biomedical publication details. (PubMed Database, 2026, PMID 42300751)
• Jun Biomedical publication details. (PubMed Database, 2026, PMID 42324976)
• Jul Nanocurcumin attenuates brain injury in rats with desert dry‑heat‑induced exertional heat stroke by suppressing TLR4/MyD88/NF‑κB signaling. (Molecular medicine reports, 2026, PMID 42396648): "Excessive activation of inflammatory signaling pathways, notably the Toll-like receptor (TLR)4/myeloid differentiation factor 88 (MyD88)/NF-κB axis, critically contributes to brain damage and neuroendocrine dysfunction in EHS."
• Jun Biomedical publication details. (PubMed Database, 2026, PMID 41874311)
• Jul Prolonged KRAS-MAPK Inhibition Induces Interferon Signaling That Promotes Cell State Transition and Confers Therapeutic Vulnerabilities. (Cancer research, 2026, PMID 42008116): "Sustained KRAS-MAPK inhibition induced interferon (IFN) and NF-κB signaling and promoted cell state change mimicking an EMT state associated with drug resistance."
• Jun Biomedical publication details. (PubMed Database, 2026, PMID 42388022)
• Jun Biomedical publication details. (PubMed Database, 2026, PMID 42043451)
• Jun Biomedical publication details. (PubMed Database, 2026, PMID 42312430)